|
1
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA;
Gynecologic Oncology Group, : Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ai Z, Lu Y, Qiu S and Fan Z: Overcoming
cisplatin resistance of ovarian cancer cells by targeting
HIF-1-regulated cancer metabolism. Cancer Lett. 373:36–44. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu W, Fan L, Bao Z, Zhang Y, Peng Y, Shao
M, Xiang Y, Zhang X, Wang Q and Tao L: The cytoplasmic
translocation of Cx32 mediates cisplatin resistance in ovarian
cancer cells. Biochem Biophys Res Commun. 487:292–299. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kanczuga-Koda L, Koda M, Sulkowski S,
Wincewicz A, Zalewski B and Sulkowska M: Gradual loss of functional
gap junction within progression of colorectal cancer-a shift from
membranous CX32 and CX43 expression to cytoplasmic pattern during
colorectal carcinogenesis. In Vivo. 24:101–107. 2010.PubMed/NCBI
|
|
8
|
Kar R, Batra N, Riquelme MA and Jiang JX:
Biological role of connexin intercellular channels and
hemichannels. Arch Biochem Biophys. 524:2–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kumar NM and Gilula NB: The gap junction
communication channel. Cell. 84:381–388. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang J, Qin G, Luo M, Chen J, Zhang Q, Li
L, Pan L and Qin S: Reciprocal positive regulation between Cx26 and
PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC
cells via GJIC-independent induction of EMT. Cell Death Dis.
6:e18292015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang Y, Zhu J, Zhang N, Zhao Y, Li WY,
Zhao FY, Ou YR, Qin SK and Wu Q: Impaired gap junctions in human
hepatocellular carcinoma limit intrinsic oxaliplatin
chemosensitivity: A key role of connexin 26. Int J Oncol.
48:703–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murphy SF, Varghese RT, Lamouille S, Guo
S, Pridham KJ, Kanabur P, Osimani AM, Sharma S, Jourdan J, Rodgers
CM, et al: Connexin 43 inhibition sensitizes chemoresistant
glioblastoma Cells to Temozolomide. Cancer Res. 76:139–149. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang SQ, Zhang SW, Zhang CZ, Zhao ZY and
Wang YJ: Connexin 43 enhances oxaliplatin cytotoxicity in
colorectal cancer cell lines. Cell Mol Biol. 63:53–58. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Y, Lai Y, Ge H, Guo Y, Feng X, Song
J, Wang Q, Fan L, Peng Y, Cao M, et al: Non-junctional Cx32
mediates anti-apoptotic and pro-tumor effects via epidermal growth
factor receptor in human cervical cancer cells. Cell Death Dis.
8:e27732017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lai Y, Fan L, Zhao Y, Ge H, Feng X, Wang
Q, Zhang X, Peng Y, Wang X and Tao L: Cx32 suppresses extrinsic
apoptosis in human cervical cancer cells via the NF-κB signalling
pathway. Int J Oncol. 51:1159–1168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Q, Yang Z, Nie Y, Shi Y and Fan D:
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and
lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kathawala RJ, Gupta P, Ashby CR Jr and
Chen ZS: The modulation of ABC transporter-mediated multidrug
resistance in cancer: A review of the past decade. Drug Resist
Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O'Grady S, Finn SP, Cuffe S, Richard DJ,
O'Byrne KJ and Barr MP: The role of DNA repair pathways in
cisplatin resistant lung cancer. Cancer Treat Rev. 40:1161–1170.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim IS, Ganesan P and Choi DK: Cx43
mediates resistance against MPP+-induced apoptosis in
SH-SY5Y neuroblastoma cells via modulating the mitochondrial
apoptosis pathway. Int J Mol Sci. 17(pii): E18192016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu D, Zhou H, Wu J, Liu W, Li Y, Shi G,
Yue X, Sun X, Zhao Y, Hu X, et al: Infection by Cx43 adenovirus
increased chemotherapy sensitivity in human gastric cancer BGC-823
cells: Not involving in induction of cell apoptosis. Gene.
574:217–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takahata C, Masuda Y, Takedachi A, Tanaka
K, Iwai S and Kuraoka I: Repair synthesis step involving ERCC1-XPF
participates in DNA repair of the Top1-DNA damage complex.
Carcinogenesis. 36:841–851. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McNeil EM and Melton DW: DNA repair
endonuclease ERCC1-XPF as a novel therapeutic target to overcome
chemoresistance in cancer therapy. Nucleic Acids Res.
40:9990–10004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Tao L, Fan L, Peng Y, Yang K,
Zhao Y, Song Q and Wang Q: Different gap junction-propagated
effects on cisplatin transfer result in opposite responses to
cisplatin in normal cells versus tumor cells. Sci Rep.
5:25632015.
|
|
27
|
Norouzi-Barough L, Sarookhani MR, Sharifi
M, Moghbelinejad S, Jangjoo S and Salehi R: Molecular mechanisms of
drug resistance in ovarian cancer. J Cell Physiol. 233:4546–4562.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mohammad RM, Muqbil I, Lowe L, Yedjou C,
Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al:
Broad targeting of resistance to apoptosis in cancer. Semin Cancer
Biol. 35 (Suppl):S78–S103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Seshacharyulu P, Ponnusamy MP, Haridas D,
Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway
in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
